Simparica For Dogs 11.1-22 lbs ( 5.1-10 kg)

Description

Simparica For Dogs 11.1-22 lbs (5.1-10 kg) is a monthly oral chewable tablet manufactured by Zoetis, providing treatment and prevention of fleas and six tick species in a single monthly dose. The 11.1–22 lbs variant delivers 20 mg sarolaner per tablet, calibrated to a minimum effective dose of approximately 0.91 mg/lb (2 mg/kg) across the 5.1–10 kg bracket. The liver-flavored chewable format eliminates the coat parting and skin contact required by topical spot-on application.

Recommended for

Dogs weighing 11.1–22 lbs (5.1–10 kg), 6 months of age and older.

Indication/Coverage

For dogs suffering from, or at risk from, mixed parasitic infections:

• Flea treatment and prevention: Eliminates adult Ctenocephalides felis and suppresses reinfestation; fleas are killed prior to egg deposition for at least 35 days per dose, disrupting environmental flea cycling.
• Lone star tick treatment and control: Controls adult Amblyomma americanum infestations with sustained efficacy maintained through 30 days post-administration.
• Gulf Coast tick treatment and control: Controls adult Amblyomma maculatum infestations for one full month per dose.
• American dog tick treatment and control: Controls adult Dermacentor variabilis infestations for one month per dose.
• Black-legged tick treatment and control: Controls adult Ixodes scapularis infestations for one month; additionally indicated for prevention of Borrelia burgdorferi infection by eliminating the vector tick before bacterial transmission can occur.
• Brown dog tick treatment and control: Controls adult Rhipicephalus sanguineus infestations for one month per dose.
• Asian longhorned tick treatment and control: Controls adult Haemaphysalis longicornis infestations for one month per dose.

Key Benefits

The following are specific to the 11.1–22 lbs (5.1–10 kg) tablet, based on Zoetis-labeled efficacy data:

• Mid-size dog dosing precision: The 20 mg tablet delivers exactly 2 mg/kg at 22 lb (10 kg), the upper boundary, meeting the minimum therapeutic threshold without underdosing dogs at any point within this range .
• Seven-species ectoparasite reach: One monthly tablet addresses all six tick species of regulatory concern in the U.S. alongside Ctenocephalides felis fleas, including the expanding Haemaphysalis longicornis
• Early flea kill: Sarolaner begins killing fleas within 3 hours of the initial oral dose, with laboratory data confirming 96.2% or greater flea reduction within 8 hours of infestation.
• Environmental cycle interruption: Treated dogs carry no viable flea eggs for at least 35 days post-dose, preventing larval development in the home environment rather than solely reducing adult counts on the host.
• Borrelia burgdorferi protection: By eliminating Ixodes scapularis before the bacterial transmission window opens, Simparica provides documented Lyme disease risk reduction in endemic geographic zones.
• Consistent field performance: Across a 90-day U.S. multi-site field study, flea reduction reached 99.4% at Day 30, 99.8% at Day 60, and 100% at Day 90 under real-world household infestation conditions.
• Coat-independent delivery: Oral chewable administration bypasses the absorption variability associated with topical spot-ons in dogs with heavy, oily, or water-exposed coats, ensuring full dose delivery regardless of coat condition.

Caution

Hazards to Humans

Store the tablet out of children’s reach. If accidental human ingestion occurs, contact a healthcare professional immediately. Always wash your hands with soap and water after handling the tablet and keep it away from food, food preparation surfaces, and animal feed.

Hazards to Domestic Animals

For oral administration in dogs only; not labeled for cats. This tablet is indicated for dogs 6 months of age and older with a confirmed minimum weight of 11.1 lbs (5.1 kg). Prior to use in debilitated, aged, pregnant, or nursing animals, consult a veterinarian. Individual hypersensitivity reactions occur rarely. Sarolaner is an isoxazoline-class compound subject to the FDA’s 2018 mandatory neurological adverse event labeling requirement; dogs with a seizure history or active neurological disorder should not receive this product without veterinary clearance. Concurrent medication interactions have not been fully characterized; veterinary guidance is warranted before combining with other therapies.

Possible Side Effects

After each monthly dose, monitor your dog for any unusual reactions over the next 24 hours, especially during the first 3 hours when the medication reaches its highest blood concentration.

Adverse reactions identified through Zoetis clinical trials and post-approval FDA CVM reporting are listed below in decreasing order of frequency:

• Vomiting: Recorded in 0.95% of sarolaner-treated dogs in the controlled U.S. field study; observe for vomiting within the first 3 hours of administration when absorption is still in progress, and monitor for any adverse reactions over the following 24 hours, contacting your veterinarian if either occurs.
• Diarrhea: Observed in 0.63% of treated dogs during clinical evaluation; post-approval surveillance additionally documents cases involving blood in the stool.
• Lethargy: Present in 0.32% of treated dogs in the field study and corroborated through post-market adverse event data.
• Neurologic signs: Tremors, ataxia, reduced conscious proprioception, and seizures have been reported across the isoxazoline class in dogs of all neurological histories; these events apply to the 11.1–22 lb weight range.
• Further post-approval events: Anorexia, pruritus, hypersalivation, and hyperactivity have been captured in FDA CVM adverse drug experience reports for sarolaner.